Literature DB >> 26482480

Cystine accumulation attenuates insulin release from the pancreatic β-cell due to elevated oxidative stress and decreased ATP levels.

Bernadette McEvoy1, Rodolfo Sumayao1, Craig Slattery1, Tara McMorrow1, Philip Newsholme2.   

Abstract

The pancreatic β-cell has reduced antioxidant defences making it more susceptible to oxidative stress. In cystinosis, a lysosomal storage disorder, an altered redox state may contribute to cellular dysfunction. This rare disease is caused by an abnormal lysosomal cystine transporter, cystinosin, which causes excessive accumulation of cystine in the lysosome. Cystinosis associated kidney damage and dysfunction leads to the Fanconi syndrome and ultimately end-stage renal disease. Following kidney transplant, cystine accumulation in other organs including the pancreas leads to multi-organ dysfunction. In this study, a Ctns gene knockdown model of cystinosis was developed in the BRIN-BD11 rat clonal pancreatic β-cell line using Ctns-targeting siRNA. Additionally there was reduced cystinosin expression, while cell cystine levels were similarly elevated to the cystinotic state. Decreased levels of chronic (24 h) and acute (20 min) nutrient-stimulated insulin secretion were observed. This decrease may be due to depressed ATP generation particularly from glycolysis. Increased ATP production and the ATP/ADP ratio are essential for insulin secretion. Oxidised glutathione levels were augmented, resulting in a lower [glutathione/oxidised glutathione] redox potential. Additionally, the mitochondrial membrane potential was reduced, apoptosis levels were elevated, as were markers of oxidative stress, including reactive oxygen species, superoxide and hydrogen peroxide. Furthermore, the basal and activated phosphorylated forms of the redox-sensitive transcription factor NF-κB were increased in cells with silenced Ctns. From this study, the cystinotic-like pancreatic β-cell model demonstrated that the altered oxidative status of the cell, resulted in depressed mitochondrial function and pathways of ATP production, causing reduced nutrient-stimulated insulin secretion.
© 2015 The Authors. The Journal of Physiology © 2015 The Physiological Society.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26482480      PMCID: PMC4667001          DOI: 10.1113/JP271237

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  73 in total

1.  Characterization of a novel glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by electrofusion.

Authors:  N H McClenaghan; C R Barnett; E Ah-Sing; Y H Abdel-Wahab; F P O'Harte; T W Yoon; S K Swanston-Flatt; P R Flatt
Journal:  Diabetes       Date:  1996-08       Impact factor: 9.461

2.  Role of adenosine triphosphate (ATP) and NaK ATPase in the inhibition of proximal tubule transport with intracellular cystine loading.

Authors:  C Coor; R F Salmon; R Quigley; D Marver; M Baum
Journal:  J Clin Invest       Date:  1991-03       Impact factor: 14.808

3.  Effect of cystine loading on substrate oxidation by rat renal tubules.

Authors:  J W Foreman; L L Benson
Journal:  Pediatr Nephrol       Date:  1990-05       Impact factor: 3.714

4.  Course of nephropathic cystinosis after age 10 years.

Authors:  W A Gahl; J A Schneider; J G Thoene; R Chesney
Journal:  J Pediatr       Date:  1986-10       Impact factor: 4.406

Review 5.  The pathogenesis of cystinosis: mechanisms beyond cystine accumulation.

Authors:  Martijn J Wilmer; Francesco Emma; Elena N Levtchenko
Journal:  Am J Physiol Renal Physiol       Date:  2010-09-08

6.  Microtiter plate assay for the measurement of glutathione and glutathione disulfide in large numbers of biological samples.

Authors:  M A Baker; G J Cerniglia; A Zaman
Journal:  Anal Biochem       Date:  1990-11-01       Impact factor: 3.365

7.  Cystine transport is defective in isolated leukocyte lysosomes from patients with cystinosis.

Authors:  W A Gahl; N Bashan; F Tietze; I Bernardini; J D Schulman
Journal:  Science       Date:  1982-09-24       Impact factor: 47.728

8.  Pancreatic endocrine insufficiency in posttransplant cystinosis.

Authors:  B Fivush; O C Green; C C Porter; J W Balfe; S O'Regan; W A Gahl
Journal:  Am J Dis Child       Date:  1987-10

9.  Infantile cystinosis and insulin-dependent diabetes mellitus.

Authors:  A Ammenti; A Grossi; S Bernasconi
Journal:  Eur J Pediatr       Date:  1986-12       Impact factor: 3.183

10.  Classic nephropathic cystinosis as an adult disease.

Authors:  D S Theodoropoulos; D Krasnewich; M I Kaiser-Kupfer; W A Gahl
Journal:  JAMA       Date:  1993-11-10       Impact factor: 56.272

View more
  6 in total

1.  Impact of atypical mitochondrial cyclic-AMP level in nephropathic cystinosis.

Authors:  Francesco Bellomo; Anna Signorile; Grazia Tamma; Marianna Ranieri; Francesco Emma; Domenico De Rasmo
Journal:  Cell Mol Life Sci       Date:  2018-03-16       Impact factor: 9.261

Review 2.  The Nrf2/Keap1/ARE Pathway and Oxidative Stress as a Therapeutic Target in Type II Diabetes Mellitus.

Authors:  Joshua A David; William J Rifkin; Piul S Rabbani; Daniel J Ceradini
Journal:  J Diabetes Res       Date:  2017-08-20       Impact factor: 4.011

Review 3.  Paraoxonase-1 as a Regulator of Glucose and Lipid Homeostasis: Impact on the Onset and Progression of Metabolic Disorders.

Authors:  Maria João Meneses; Regina Silvestre; Inês Sousa-Lima; Maria Paula Macedo
Journal:  Int J Mol Sci       Date:  2019-08-19       Impact factor: 5.923

Review 4.  In Vitro and In Vivo Models to Study Nephropathic Cystinosis.

Authors:  Pang Yuk Cheung; Patrick T Harrison; Alan J Davidson; Jennifer A Hollywood
Journal:  Cells       Date:  2021-12-21       Impact factor: 6.600

Review 5.  Programmed Cell Death in Cystinosis.

Authors:  Elizabeth G Ames; Jess G Thoene
Journal:  Cells       Date:  2022-02-15       Impact factor: 6.600

Review 6.  The Role of SLC7A11 in Cancer: Friend or Foe?

Authors:  Sijia Li; Zhenyao Lu; Runbin Sun; Suhan Guo; Fangfang Gao; Bei Cao; Jiye Aa
Journal:  Cancers (Basel)       Date:  2022-06-22       Impact factor: 6.575

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.